Spotlight survey: immuno-oncology

Question Title

* 1. What is your specific interest in immuno-oncology?

Therapeutic antibodies

Cell therapy/ vaccination

Oncolytic viruses

Retargeting of oncolytic compounds

Chemotherapy or radiotherapy

Other – please specify

Question Title

* 2. What, if any, do you feel are the key benefits associated with cancer immunotherapies? Please select all responses that apply.

Fewer side effects

Targeted mechanism of action

Efficacy – therapeutic benefits

Can be used in combination with other therapies

Convenience/ ease of administration

Patient acceptance/ compliance

Other – please specify

Question Title

* 3. In your opinion, which immunotherapy combination has the most clinical potential?

Question Title

* 4. What, if any, do you see as the key limitation of current cancer immunotherapies?

Efficacy concerns

Cost/ reimbursement

Side effects/ toxicity

Mechanism of action – difficulties selecting antigens/ tumor cells

Limited clinical evidence

Limited indications/ usage

Lack of familiarity

Poor availability

Other – please specify

Other (please specify)

Question Title

* 5. What is the biggest challenge in developing novel and effective immunotherapies to treat cancer?

Lack of translatable animal models

Lack of predictive biomarkers

Demonstrating efficacy

The non-traditional dose-response relationship

Clinical trial recruitment and management

Scaling up and manufacturing

Securing reimbursement

Other – please specify

Question Title

* 6. Assuming that CME courses, conferences and journal publications are primary channels to stay informed on advances in immunotherapy and diagnostic tests. Please rank these additional opportunities (1 being most important) in order of importance for you to stay up-to-date

Question Title

* 7. How would you rate your patient’s receptivity to cancer immunotherapies as a treatment option?

0–10%

10–20%

30–40%

40–50%

50–60%

60–70%

70–80%

80–90%

90–100%

Question Title

* 8. What percentage of your patients currently being treated with pharmacological therapy are receiving an immunotherapy?

0–10%

10–20%

30–40%

40–50%

50–60%

60–70%

70–80%

80–90%

90–100%

Question Title

* 9. In 5 years, what percentage of your pharmacologically treated patients do you estimate will be receiving an immunotherapy?

0–10%

10–20%

30–40%

40–50%

50–60%

60–70%

70–80%

80–90%

90–100%

Question Title

* 10. In your opinion, do current immunotherapies offer good value in terms of cost per quality adjusted life year? Please explain your reasoning

Yes